HIV Market Opportunity Overview

• Worldwide, an estimated 39.5 million people are living with HIV¹
• Between 1.04 and 1.85 million people are living with HIV in the U.S.²
• An estimated 2.2 million people in Europe are living with HIV³
• Emergence of drug resistance has thwarted global efforts to effectively manage HIV infection⁴
• There is a need for safe and convenient drug combinations to improve patient compliance

RDEA806, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Currently, there are four approved NNRTIs, but they have several therapeutic limitations, including the development of HIV strains that are resistant to other drugs within the class; unacceptable adverse side effects; reproductive toxicity, which limits the use of the compounds in women of childbearing potential; and drug-to-drug interactions.

RDEA806 has successfully completed Phase 1 and Phase 2a studies and has been evaluated in over 250 subjects.  Results from a Phase 2a monotherapy proof-of-concept study of RDEA806 demonstrated placebo-adjusted plasma viral load reductions of up to 2.0 log10 on day 8 with once-daily dosing of RDEA806.  In addition, all dosing regimens tested were well-tolerated in this study.  

RDEA427, a next-generation NNRTI, is from a chemical class that is distinct from the RDEA806 chemical class. Based on preclinical results, RDEA427 demonstrates many of the same positive attributes as RDEA806, but is more potent, has superior pharmacokinetic properties, and has even greater activity against a wide range of drug-resistant viral isolates than RDEA806. We have evaluated RDEA427 in a human microdose pharmacokinetic study. Beyond RDEA427 is our 900 Series of NNRTIs; these are chemically distinct from both the RDEA806 and RDEA427 classes of molecules.

The timing of future studies with our NNRTIs will be determined in part by the results of our partnering efforts.

For more information regarding these programs please click here to view our most recent company presentation.